Abstract:Objective:To explore the efficacy and influencing factors of radiofrequency ablation (RFA) in the treatment of colorectal cancer liver metastases (CRLM).Methods:The clinical and imaging data of 281 patients (477 intrahepatic metastatic tumors) who received percutaneous RFA treatment in Sir Run Run Shaw Hospital, Zhejiang University School of Medicine from December 2009 to December 2020 were retrospectively analyzed. Factors that may affect the efficacy of RFA were recorded, including carcinoembryonic antigen (CEA), differentiation, extrahepatic metastasis, tumor location and size, complications and other information. Patients were followed up through hospital admissions, telephone, etc. The primary endpoints were overall survival (OS) and local tumor progression-free survival (LTPFS). Univariate and multivariate logistic regression models were used to identify predictors of residual tumor. Univariate and multivariate Cox proportional hazards regression were used to identify the influencing factors of LTPFS and OS. The median LTPFS and OS were estimated by the Kaplan-Meier curve and compared by the log-rank test.Results:After RFA, 68 (14.3%) tumor residues were observed. Multivariate logistic regression showed that the risk factors for residual tumor were size ≥20 mm, high-risk and perivascular location, and minimal ablative margin<5 mm. During the follow-up period, the main complication rate was 4.3% (12/281) and the fatality rate was 31.3% (88/281). At the same time, local tumor progression was found in 167 (35.0%) lesions post-RFA. The median time of LTPFS and OS estimated by the Kaplan Meier method were 35.0 (95%CI 26.53-43.48) and 44.0 (95%CI 29.70-58.30) months, respectively. The cumulative proportion of LTPFS and OS were 37.2% and 40.4% respectively in the 5th year. Multivariate Cox proportional hazard regression showed that CEA≥30 ng/ml, tumor size ≥20 mm, and minimal ablative margin<5 mm were risk factors for LTPFS; extrahepatic metastasis, tumor burden>30 mm, and lesion with minimal ablative margin<5 mm were independent risk factors for OS; re-intervention was an independent protective factor for OS.Conclusions:Adequate ablative margin and less tumor burden were beneficial to local tumor control and long-term survival of patients in the RFA treatment; the existence of extrahepatic metastasis was an important risk factor for OS, and re-interventional therapy was beneficial to extend OS.

Therapeutic Effects of Radio Frequency Ablation in Lung Tumor Treatment

Efficacy and Potential MicroRNA Mechanism for Computed Tomography-Guided Percutaneous Radiofrequency Ablation of Primary Lung Cancer and Lung Metastasis from Liver Cancer

Radiofrequency ablation for the treatment of lung neoplasms: a retrospective study of 329 cases]

Observation of Therapeutic Effect of Solid Tumor in Lung after Radiofrequency Ablation

Clinical observation of radiofrequency ablation for treating patients with lung cancer

Current Progression of Radiofrequency Ablation (RFA) in Clinical Application of Lung Cancer Therapy

Radiofrequency Ablation of Advanced Lung Tumors: Imaging Features, Local Control, and Follow-Up Protocol.

CT-guided radiofrequency ablation for lung cancer：a retrospective analysis of 35 cases

A Systematic Review of Radiofrequency Ablation for Lung Tumors

Clinical application of percutaneous radiofrequency ablation used in treatment of advanced local lung cancer patients

Analysis of therapeutic effect and influencing factors of radiofrequency ablation for colorectal cancer liver metastases

[Percutaneous radiofrequency ablation in treatment of advanced local lung cancer: clinical analysis of 78 cases].

Clinical Effect of Percutaneous Radiofrequency Ablation for Residual Lung Metastases from Breast Cancer After Systemic Chemotherapy

[Effectiveness of radiofrequency ablation of lung tumours]

A prospective clinical trial of radiofrequency ablation for pulmonary metastases.

Radiofrequency ablation for the treatment of advanced non-small-cell lung cancer: a meta-analysis

Imaging-guided radiofrequency ablation for the treatment of tumors:its current status and progress

A Multi-Center, Prospective Study of Transbronchial Radiofrequency Ablation for Peripheral Lung Tumors: Study Progress and Initial Results

Effectiveness of Radiofrequency Ablation Therapy for Patients with Unresected Stage IA Non-Small Cell Lung Cancer.

CT-guided Percutaneous Minimally Invasive Radiofrequency Ablation for the Relief of Cancer Related Pain from Metastatic Non-Small Cell Lung Cancer Patients: a Retrospective Study.

[Expert Consensus for Image-guided Radiofrequency Ablation of Pulmonary Tumors (2018 Version)].